Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.43 |
| ▸ | PAK4 | O96013 | 1/20 | 0.43 |
| ▸ | PIM1 | P11309 | 1/20 | 0.43 |
| ▸ | PRKACA | P17612 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.43 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.43 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.43 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.43 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.41 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16746748 | 0.90 | MPO (0.46) | CDC7JAK2ROCK2MAP4K4PAK4 | |
| SCHEMBL16746855 | 0.87 | MPO (0.48) | JAK2MPOTPOCYP3A4DAO | |
| SCHEMBL64650 | 0.83 | BACE1 (0.49) | MPOALDH1A1DAORAB9ASMN1; SMN2 | |
| SCHEMBL13737667 | 0.81 | ALDH1A1 (0.44) | KDRMPOALDH1A1DAOPARP1 | |
| SCHEMBL13737504 | 0.81 | HSP90AB1 (0.53) | MKNK2GFERMPOALDH1A1DAO | |
| SCHEMBL18148766 | 0.81 | MPO (0.47) | HCAR2MPOCYP3A4DAO | |
| SCHEMBL4858684 | 0.81 | MPO (0.47) | HPGDMPOALDH1A1DAOTDP1 | |
| SCHEMBL958531 | 0.79 | TSHR (0.50) | TSHRMPOTPOCYP3A4RAB9A | |
| SCHEMBL23361673 | 0.78 | NR1H2 (0.44) | HPGDTSHRGFERHCAR2CALM1 | |
| SCHEMBL22636469 | 0.78 | MPO (0.47) | HPGDTSHRMPOALDH1A1DAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12312345-B2 | Fluoroalkyl-oxadiazoles and uses thereof | TENAYA THERAPEUTICS, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| US-20240182462-A1 | FLUOROALKYL-OXADIAZOLES AND USES THEREOF | TENAYA THERAPEUTICS, INC. | 2024-06-06 | — | — | US | disclosed |
| US-11926622-B2 | Fluoroalkyl-oxadiazoles and uses thereof | TENAYA THERAPEUTICS, INC. (US) | 2024-03-12 | — | — | US | disclosed |
| US-20230143804-A1 | FLUOROALKYL-OXADIAZOLES AND USES THEREOF | TENAYA THERAPEUTICS, INC. | 2023-05-11 | — | — | US | disclosed |
| US-11578066-B1 | Fluoroalkyl-oxadiazoles and uses thereof | TENAYA THERAPEUTICS, INC. (US) | 2023-02-14 | — | — | US | disclosed |
| EP-4076448-A1 | FLUOROALKYL-OXADIAZOLES AND USES THEREOF | Tenaya Therapeutics, Inc. (US) | 2022-10-26 | — | — | EP | disclosed |
| CN-114980887-A | Fluoroalkyl-oxadiazoles and their use | 特纳亚治疗股份有限公司 | 2022-08-30 | — | — | CN | disclosed |
| WO-2021127643-A1 | FLUOROALKYL-OXADIAZOLES AND USES THEREOF | TENAYA THERAPEUTICS, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
| EP-2488519-B1 | PYRAZOLOPYRIDINE DERIVATIVES AS ANTICANCER AGENT | PF MEDICAMENT (FR) | 2015-06-10 | — | — | EP | disclosed |
| US-8889711-B2 | Pyrazolopyridine derivatives as anticancer agent | PIERRE FABRE MEDICAMENT (FR) | 2014-11-18 | — | — | US | disclosed |
| US-20070142413-A1 | Pyrazole derivatives as inhibitors of receptor tyrosone kinases | ASTRAZENECA AB (SE) | 2007-06-21 | — | — | US | disclosed |
| CN-1905884-A | Pyrazole derivatives as inhibitors of receptor tyrosyne kinases | ASTRAZENECA AB (SE) | 2007-01-31 | — | — | CN | disclosed |
| EP-1686999-A1 | PYRAZOLE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | AstraZeneca AB (SE) | 2006-08-09 | — | — | EP | disclosed |
| US-20060074116-A1 | 3-(Heteroarylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors | ALLERGAN, INC. | 2006-04-06 | — | — | US | disclosed |
| US-7005444-B2 | 3-(heteroarylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors | ALLERGAN, INC. (US) | 2006-02-28 | — | — | US | disclosed |
| WO-2005049033-A1 | PYRAZOLE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSYNE KINASES | ASTRAZENECA AB (SE) | 2005-06-02 | — | — | WO | disclosed |
| US-20030130328-A1 | 3-(Heteroarylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors | ALLERGAN, INC. | 2003-07-10 | — | — | US | disclosed |
| US-6559173-B1 | organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation. | ALLERGAN, INC. | 2003-05-06 | — | — | US | disclosed |
| WO-2003026650-A1 | 3-(HETEROARYLAMINO)METHYLENE-1,3-DIHYDRO-2H-INDOL-2-ONES AS KINASE INHIBITORS | ALLERGAN, INC. (US) | 2003-04-03 | — | — | WO | disclosed |
| EP-0156308-A2 | Pyrazolo-[3,4-d]v-triazoles and their use | BASF Aktiengesellschaft (DE) | 1985-10-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11926622-B2 | Fluoroalkyl-oxadiazoles and uses thereof | HDAC6, HDAC1, HDAC3 | CDC7 2739/4885JAK2 1100/4885ROCK2 1107/4885 |
| US-20240182462-A1 | FLUOROALKYL-OXADIAZOLES AND USES THEREOF | HDAC6, HDAC1, HDAC3 | CDC7 2739/4885JAK2 1100/4885ROCK2 1107/4885 |
| US-12312345-B2 | Fluoroalkyl-oxadiazoles and uses thereof | HDAC6, HDAC1, HDAC3 | CDC7 2739/4885JAK2 1100/4885ROCK2 1107/4885 |
| US-11578066-B1 | Fluoroalkyl-oxadiazoles and uses thereof | HDAC6, HDAC1, HDAC3 | CDC7 2739/4885JAK2 1100/4885ROCK2 1107/4885 |
| US-20060074116-A1 | 3-(Heteroarylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors | ERBB2, MKI67, CDK2 | CDC7 182/4885JAK2 136/4885ROCK2 353/4885 |
| US-20230143804-A1 | FLUOROALKYL-OXADIAZOLES AND USES THEREOF | HDAC6, HDAC1, HDAC3 | CDC7 2044/4885JAK2 2922/4885ROCK2 1479/4885 |
| US-20070142413-A1 | Pyrazole derivatives as inhibitors of receptor tyrosone kinases | PRKDC, MUSK, LTK | CDC7 317/4885JAK2 144/4885ROCK2 730/4885 |
| US-20030130328-A1 | 3-(Heteroarylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors | ERBB2, MKI67, CDK2 | CDC7 182/4885JAK2 136/4885ROCK2 353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.